Clinical Trials Browser

NIH × Salivary Gland Neoplasms × Sorafenib × Clear all

NCT00939627 2026-03-10

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Phase 2 Completed

55 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00096512 2013-02-28

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms